Generic Name and Formulations:
Fondaparinux sodium 2.5mg/0.5mL, 5mg/0.4mL. 7.5mg/0.6mL, 10mg/0.8mL; soln for SC inj; preservative free.
Indications for ARIXTRA:
Prophylaxis of DVT in patients undergoing hip fracture surgery, or hip or knee replacement, or abdominal surgery with risk of thromboembolic complications. With warfarin: Treatment of acute pulmonary embolism (PE) (initiate in hospital), or treatment of acute DVT.
Give by SC inj. Prophylaxis: Once hemostasis is achieved, give 1st dose no earlier than 6–8hrs post-op. 2.5mg once daily for 5–9 days. Hip or knee replacement: max 11 days. Hip fracture: give for up to 24 more days (max 32 days). Abdominal: max 10 days. Treatment: (<50kg): 5mg; (50–100kg): 7.5mg; (>100kg): 10mg; for all: give once daily for at least 5 days and until INR= 2–3; usually 5–9 days; max 26 days; start warfarin usually within 72hrs.
Severe renal impairment (CrCl <30mL/min). Active major bleeding. Bacterial endocarditis. Thrombocytopenia associated with (+) in vitro test for antiplatelet antibody in presence of fondaparinux. Also for prophylaxis: body weight <50kg.
See full labeling. Increased risk of spinal/epidural hematoma in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal puncture (esp. post-op indwelling epidural use); monitor for signs/symptoms of neurological impairment. Increased risk of hemorrhage in those with bleeding disorders, acute ulcerative or angiodysplastic GI disease, hemorrhagic stroke, uncontrolled hypertension, diabetic retinopathy, recent brain, spinal, or eye surgery. Increased risk of bleeding in renal impairment and in those with low body weight (<50kg). Assess hepatic and renal function periodically; discontinue if severe renal impairment develops. Monitor closely for thrombocytopenia. Obtain CBCs, platelets, serum creatinine level, stool occult blood tests during therapy; discontinue if platelets <100,000 per mm3 or major bleeding occurs. Not interchangeable (unit-for-unit) with heparin or low molecular weight heparins. Latex allergy. Elderly. Neonates. Pregnancy. Labor & delivery. Nursing mothers.
Caution with drugs that affect hemostasis (eg, warfarin, platelet inhibitors, NSAIDs). Avoid drugs that increase risk of hemorrhage (eg, Vit. K antagonists); if co-admin necessary, monitor closely for bleeding.
Factor Xa inhibitor.
Bleeding, thrombocytopenia, local reactions (rash, pruritus, hematoma, pain), anemia, insomnia, increased wound drainage, hypokalemia, dizziness, hypotension, confusion, bullous eruption, post-op hemorrhage, purpura, elevated ALT/AST.
Prefilled syringes 2.5mg, 7.5mg, 10mg—2, 10; 5mg—10
Clinical Pain Advisor Articles
- Brain Plasticity in Patients With Complex Regional Pain Syndrome
- Perturbation-Based Rehabilitation Effective for Chronic Low Back Pain
- Cannabis Use Associated With Relationship Between Pain and Negative Affect
- FDA Expresses Safety Concern Over Kratom
- Cannabidiol Concentrations Widely Vary in Products Sold Online
- Cannabis Use Associated With Aberrant Drug Behaviors
- Walgreens to Carry Naloxone in All Pharmacies to Combat Drug Abuse
- Independent Pharmacies Expanding Services Available to Patients
- Ketamine Exhibits Effective Pain Relief for Refractory Headaches
- Pain In Elite Athletes: IOC Recommendations on Contributing Factors and Treatment Approach
- Naproxen Plus Muscle Relaxants vs Naproxen Monotherapy for Low Back Pain
- Pain Processing: Examining the Role of Oxytocin
- Short- vs Long-Acting Opioids for Osteoarthritis Pain
- Extended-Release Naltrexone Injections Reduce Opioid Dependence
- Depressive Symptoms in Medical Interns Increased With Work-Family Conflicts